Nifty Pharma Drops 1.05% as 15 of 20 Stocks Slide; Lupin, Aurobindo Pharma Lead the Fall
By Shishta Dutta | Published at: Jul 8, 2025 03:55 PM IST
Mumbai, Jul 8 – The Nifty Pharma index slipped 1.05% to 22,129.90 by 14:47 IST on Tuesday, further dropping to 0.94% by 15:04 PM IST on Tuesday, reaching 22,154.40, down from a robust opening at 22,383.40. The index fell to an intraday low of 21,987.65, although it only slightly recovered from that low.
A lot of large pharmaceutical companies, like Aurobindo Pharma, Lupin, Dr. Reddy’s, Zydus Lifesciences, Granules, Sun Pharma, and Cipla, had their stock prices drop by 1% to 3%. This was because people were worried again about U.S. trade tariffs on Indian medication exports. On the other hand, conservative firms including Divi’s Laboratories, Mankind Pharma, Natco, IPCA, Gland Pharma, and Abbott India made little advances thanks to more stable fundamentals.
This part is weak because the Nifty Pharma index fell by more than 6% in the first half of 2025, making it one of the worst-performing sectors so far. This was due to worries over export policies, global tariff concerns, and regulatory problems.
Index Movement Snapshot
| Parameter | Value |
|---|---|
| Last Price | 22,154.40 |
| Change | -210.65 |
| % Change | -0.94% |
| Open | 22,383.40 |
| Day High | 22,400.15 |
| Day Low | 21,987.65 |
| Previous Close | 22,365.05 |
| 52-Week High | 23,907.90 |
| 52-Week Low | 19,121.10 |
| Traded Volume | 1.65 Cr |
| Traded Value | ₹2,470.45 Cr |
| 1-Month Return | +3.14% |
| 1-Year Return | +9.34% |
| Advances | 5 |
| Declines | 15 |
| Unchanged | 0 |
Top 5 Gainers in Nifty Pharma (as of 14:47 IST)
| Stock | LTP (₹) | Change (₹) | % Change |
|---|---|---|---|
| Natco Pharma | 982.40 | +8.80 | +0.90% |
| Gland Pharma | 1,889.00 | +14.20 | +0.76% |
| Mankind Pharma | 2,427.80 | +17.40 | +0.72% |
| IPCA Laboratories | 1,466.70 | +8.90 | +0.61% |
| Divi’s Laboratories | 6,927.00 | +38.50 | +0.56% |
Top 5 Losers in Nifty Pharma
| Stock | LTP (₹) | Change (₹) | % Change |
|---|---|---|---|
| Aurobindo Pharma | 1,145.50 | -39.60 | -3.34% |
| Lupin | 1,917.10 | -61.50 | -3.11% |
| Granules India | 479.75 | -13.45 | -2.73% |
| Dr. Reddy’s Labs | 1,282.50 | -28.00 | -2.14% |
| Zydus Lifesciences | 982.50 | -16.30 | -1.63% |
Among the 20 index constituents, 15 stocks were in the red while only five managed to stay afloat. Notably, Aurobindo Pharma and Lupin posted the steepest intraday losses of over 3%, while Dr. Reddy’s, Granules, and Zydus also witnessed selling pressure.
On the gaining side, Natco Pharma, Gland Pharma, Mankind Pharma, IPCA Laboratories, and Divi’s Labs saw marginal upticks, with Natco leading the advances with a 0.90% rise.
Looking ahead, the near-term outlook remains cautious. July seasonality typically favors pharma—13 out of the past 16 Julys yielded positives—but returns have been uneven. Q2 earnings, movement on the U.S.–India trade front, and potential FDA inspections may drive the next leg of volatility
Stock-wise 52-Week Positioning (Select Highlights)
| Stock | % Away from 52W High | % Away from 52W Low |
|---|---|---|
| Laurus Labs | -0.73% | +86.90% |
| Divi’s Laboratories | -2.04% | +57.60% |
| Glenmark Pharma | -2.60% | +43.51% |
| Dr. Reddy’s Labs | -9.77% | +25.73% |
| Sun Pharma | -14.88% | +7.66% |
About Nifty Pharma
Nifty Pharma is a sectoral index maintained by NSE, comprising 20 pharmaceutical companies that reflect the performance of the Indian pharma industry. As of Jul 8, 2025, the index showed a YoY return of 9.34% and 3.14% gains over the past 30 days.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
